Clinical Trial: Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07264010) titled 'Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study' on Nov. 23.

Brief Summary: The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.

Study Start Date: Dec. 01

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukaemia (AML) Measurable Residual Disease (MRD)

Intervention: DRUG: Sorafenib (SORA)

Sorafenib (SORA) was administered at 400mg twice daily on days 1 to 28.

DRUG: Venetoclax (VEN)

Venetocl...